As of January 2026, more than 3,063 personal injury lawsuits alleging gastroparesis, ileus, and intestinal obstruction from Ozempic and related GLP-1 medications are consolidated in MDL 3094 in the Eastern District of Pennsylvania. The litigation continues to advance toward bellwether trials expected later this year, though settlements remain unlikely until late 2026 at the earliest. Plaintiffs who took Novo Nordisk’s semaglutide drugs””including Ozempic, Wegovy, and Rybelsus””and developed severe stomach paralysis are pursuing failure-to-warn claims, arguing the pharmaceutical company did not adequately disclose the risk of debilitating gastrointestinal injuries. The path forward for these cases narrowed significantly in 2025 when the court allowed core failure-to-warn claims to proceed but imposed strict evidentiary requirements.
Judge Marston ruled that plaintiffs must present objective diagnostic testing””such as scintigraphy, breath testing, or wireless motility capsule studies””to confirm their gastric injuries. For example, a plaintiff who experienced months of severe vomiting but never underwent formal gastric emptying tests may find their case excluded from the MDL if defendants’ pending arguments succeed. This diagnostic threshold has become a critical gatekeeping issue in the litigation. This article covers the current status of the MDL, key court rulings affecting plaintiffs, the timeline for upcoming proceedings, the types of injuries alleged, factors that may influence case values, and what claimants should expect as the litigation moves toward trial.
Table of Contents
- What Is the Current Status of the Ozempic Gastroparesis MDL?
- Court Rulings Have Created Significant Hurdles for Some Plaintiffs
- What Injuries Are Alleged in the Ozempic Litigation?
- How Case Values May Differ Among Plaintiffs
- What Should Plaintiffs Expect From the Bellwether Process?
- The Diagnostic Documentation Problem
- What Comes Next for the Ozempic Litigation
- Conclusion
What Is the Current Status of the Ozempic Gastroparesis MDL?
MDL 3094 has grown substantially since its formation, now encompassing 3,063 personal injury cases specifically involving gastroparesis and related gastrointestinal conditions. The multidistrict litigation consolidates claims against Novo Nordisk from plaintiffs across the country who allege the company’s GLP-1 receptor agonist medications caused severe stomach paralysis and intestinal blockages. A status conference held on January 22, 2026, addressed gastroparesis cases specifically, keeping the litigation on track toward trial. Expert discovery in the MDL is scheduled to close in March 2026, a significant milestone that will largely determine which scientific and medical testimony each side can present at trial.
This phase has involved extensive depositions of gastroenterologists, pharmacologists, and regulatory experts who will testify about whether Novo Nordisk knew or should have known about the gastroparesis risks and whether the company’s warning labels were adequate. The discovery process has also included battles over internal company documents related to drug safety monitoring. Compared to other pharmaceutical MDLs, the Ozempic litigation has moved at a moderate pace. For context, the Zantac MDL saw its first bellwether trial roughly three years after formation, while some other drug injury MDLs have taken five years or longer to reach trial. The Ozempic MDL appears positioned for bellwether trials in late 2026, though this timeline could shift depending on the resolution of pending motions regarding plaintiff qualification standards.
Court Rulings Have Created Significant Hurdles for Some Plaintiffs
The 2025 rulings from Judge Marston fundamentally changed the landscape of this litigation by requiring plaintiffs to present objective diagnostic evidence of gastric injury. This means that subjective symptoms alone””even severe and prolonged vomiting, nausea, and abdominal pain””will not suffice to keep a case in the MDL. Plaintiffs must demonstrate through recognized medical testing that their stomach motility was objectively impaired. The three accepted diagnostic methods carry different implications for plaintiffs. Gastric emptying scintigraphy, considered the gold standard, involves consuming a meal containing a small amount of radioactive material and tracking how quickly it leaves the stomach.
Breath testing measures carbon dioxide isotopes after eating a specially prepared meal. Wireless motility capsule studies involve swallowing a small electronic device that transmits data as it passes through the digestive system. However, if a plaintiff’s doctor treated them symptomatically without ordering these specific tests””which is not uncommon in clinical practice””they may face exclusion from the litigation. This evidentiary requirement creates a significant limitation for potential claimants. Patients who stopped taking Ozempic after experiencing symptoms and recovered without formal diagnostic workup may lack the documentation needed to proceed. Defense attorneys have filed motions arguing that plaintiffs without proper gastric emptying tests should be dismissed, and the court’s ruling on these arguments could substantially reduce the number of viable cases in the MDL.
What Injuries Are Alleged in the Ozempic Litigation?
The primary injury at the center of this litigation is gastroparesis, a condition where the stomach muscles fail to function properly, causing food to remain in the stomach far longer than normal. Plaintiffs describe debilitating cycles of nausea and vomiting that required emergency room visits and hospitalizations. Some developed such severe symptoms that they could not maintain adequate nutrition and required feeding tubes or intravenous nutritional support. Beyond gastroparesis, plaintiffs have alleged ileus and intestinal blockages that in some cases required surgical intervention. Pancreatitis claims involve inflammation of the pancreas that can cause excruciating abdominal pain and potentially life-threatening complications.
Vitamin deficiencies have resulted from prolonged inability to properly digest and absorb nutrients. Blood clots and vision loss“”specifically non-arteritic anterior ischemic optic neuropathy (NAION)””represent separate but related tracks within the broader GLP-1 litigation, with vision loss cases proceeding on their own trajectory. The FDA Adverse Event Reporting System has logged nearly 500 deaths in the United States linked to semaglutide medications. While adverse event reports do not establish causation, this figure has featured prominently in plaintiffs’ arguments about the scope of potential harm from these drugs. For example, families who lost loved ones after the patient developed severe gastroparesis complications have pointed to these reports as evidence that the risks extended beyond what the drug labels conveyed.
How Case Values May Differ Among Plaintiffs
Not all Ozempic gastroparesis cases will have equivalent value if settlements eventually occur or verdicts are reached. Legal experts analyzing the litigation have identified long-term permanent injury as the primary factor likely to drive higher compensation. A plaintiff who developed chronic gastroparesis requiring ongoing treatment and lifestyle modifications will likely see a substantially different outcome than someone whose symptoms resolved after discontinuing the medication. The severity and duration of suffering matters considerably. Cases involving multiple hospitalizations, surgical interventions, feeding tube placement, or permanent dietary restrictions present stronger damages claims than cases with short-term symptoms that resolved with conservative treatment.
Documented medical expenses, lost wages, and evidence of diminished quality of life all factor into potential case values. Plaintiffs who can demonstrate through medical records that their injuries fundamentally altered their daily functioning will generally have stronger cases. However, cases involving minimal or short-term suffering are unlikely to receive significant compensation, even if the plaintiff can prove they took the drug and experienced some adverse effects. This represents a practical reality of mass tort litigation: resources for settlement funds are finite, and both courts and parties typically prioritize cases with more substantial documented harm. Plaintiffs with marginal injuries may find that the cost and effort of litigation exceeds any potential recovery.
What Should Plaintiffs Expect From the Bellwether Process?
Bellwether trials, expected to begin later in 2026, will test representative cases before juries to help both sides evaluate the strength of their arguments. These trials do not directly determine outcomes for all plaintiffs, but they heavily influence settlement negotiations by revealing how juries respond to the evidence. A strong plaintiff verdict could pressure Novo Nordisk toward settlement discussions, while defense victories could reduce settlement leverage for remaining plaintiffs. The selection of bellwether cases involves strategic considerations from both sides. Plaintiffs’ attorneys typically prefer cases with clear diagnostic evidence, severe documented injuries, and sympathetic facts.
Defense attorneys often seek cases with confounding factors””plaintiffs with pre-existing conditions, incomplete medical records, or other potential causes for their symptoms. The cases ultimately selected for bellwether trials will not be perfectly representative of all MDL plaintiffs, which is a limitation of the bellwether process. One warning for plaintiffs: bellwether outcomes do not guarantee similar results for individual cases. A plaintiff whose case closely resembles a successful bellwether might reasonably expect favorable treatment in settlement negotiations, but unique facts in each case can produce different outcomes. Plaintiffs should discuss with their attorneys how their specific circumstances compare to the bellwether cases as those trials conclude.
The Diagnostic Documentation Problem
A substantial number of potential plaintiffs face a documentation gap that could prove fatal to their claims. Many patients who experienced gastroparesis symptoms were treated by primary care physicians or emergency room doctors who managed symptoms without ordering the specific gastric emptying studies now required by the court. This reflects standard medical practice in many cases””if symptoms resolve after stopping a medication, extensive diagnostic testing may seem unnecessary from a clinical standpoint.
For example, a patient who experienced two months of severe nausea and vomiting while taking Ozempic, visited the emergency room twice, and recovered after discontinuing the drug might have strong circumstantial evidence of drug-induced gastroparesis. However, if that patient’s doctors treated the symptoms without ordering scintigraphy or breath testing, the court’s evidentiary requirements could exclude them from the MDL. Plaintiffs in this situation should consult with their attorneys about whether obtaining diagnostic testing now””potentially years after their initial symptoms””could still support their claims.
What Comes Next for the Ozempic Litigation
The March 2026 close of expert discovery will mark a turning point in the litigation. After that deadline, both sides will have largely fixed their expert witness lineups, and the focus will shift to trial preparation. Motion practice will likely intensify as defendants seek to exclude plaintiffs who cannot meet the diagnostic testing requirements and challenge the admissibility of certain expert testimony.
Settlement discussions remain speculative at this stage. Novo Nordisk has not indicated willingness to settle, and plaintiffs’ attorneys have suggested that meaningful negotiations are unlikely until after bellwether trials provide both sides with jury feedback on liability and damages arguments. For plaintiffs currently in the MDL or considering filing claims, the realistic timeline extends well into late 2026 or beyond before any resolution becomes likely. Those with documented, severe injuries and proper diagnostic evidence are best positioned for the litigation ahead.
Conclusion
The Ozempic gastroparesis litigation has reached a critical phase, with more than 3,000 cases consolidated in MDL 3094 and bellwether trials on the horizon for late 2026. The court’s requirement for objective diagnostic testing has created a meaningful barrier for some plaintiffs while allowing those with documented gastric injuries to proceed with their failure-to-warn claims against Novo Nordisk.
Plaintiffs considering joining the litigation should prioritize obtaining and organizing their medical records, particularly any gastric emptying studies or documentation of hospitalizations related to gastroparesis symptoms. Those already in the MDL should stay in close contact with their attorneys as expert discovery closes and bellwether case selection proceeds. The coming months will substantially shape the trajectory of this litigation and ultimately determine what compensation, if any, injured plaintiffs may recover.